BioCentury
ARTICLE | Politics, Policy & Law

Balancing act

Gottlieb’s priorities: implementing Cures Act, promoting generic competition

March 31, 2017 11:45 PM UTC

Scott Gottlieb’s toughest political challenge before and after confirmation as FDA commissioner will not be from a hostile Congress, but rather from White House officials who believe the agency is an impediment to medical progress and should get out of the way of patients who want to try unapproved drugs.

His first stop on the path to FDA’s White Oak campus will be the offices of members of the Senate Health, Education, Labor and Pensions (HELP) Committee, which must approve his nomination before it can be considered by the full Senate. ...